



## **ASX ANNOUNCEMENT**

### **Imugene – Expiry of Unlisted Options**

Please be advised that the following unlisted incentive options have lapsed:-

<b>Number of Options</b>	<b>Exercise Price</b>	<b>Expiry Date of Options</b>
4,350,000	\$0.250	31-Dec-09

These options were granted to Directors and key executives on 18 January 2007.

#### **About Imugene**

Imugene specialises in commercialising animal health products for production animals including pigs and poultry.

Imugene owns the worldwide rights to the *Fowl Adenoviral Vector Delivery System* for poultry and the *Porcine Adenoviral Vector Delivery System* for pigs. Since establishing a laboratory at La-Trobe University, Victoria, additional vaccine technology has been developed for the pig & poultry industries.

A Strategic Alliance with Merial Limited agreed in December 2008, provides the strength of Merial's vast experience and infrastructure to the development of Imugene's innovative range of vaccine candidates. In return for exclusivity over the Imugene technology, Imugene will receive annual payments, milestone fees and royalties.

Imugene's poultry and pig vaccine portfolio is targeting a worldwide US\$3 billion annual market with several lead vaccine products under development and a strong product pipeline. Consumer demands for disease free and residue free food will bolster Imugene's prospects.

For more information please visit the Imugene Website [www.imugene.com](http://www.imugene.com) or contact:

**Dr Warwick Lamb**  
**Managing Director**  
**+61 2 9870 7330**

**Mr Graham Dowland**  
**Executive Chairman**  
**+61 8 9440 2660**

ABN 99 009 179 551

Registered Office  
Level 20, Allendale Square, 77 St Georges Terrace, Perth WA 6000  
Tel +61 8 94402660 Fax +61 8 9 4402699

[www.imugene.com](http://www.imugene.com)